View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 9, 2022

Palatin begins subject recruitment for ulcerative colitis treatment trial

The study will evaluate the tolerability, biomarkers, pharmacokinetics, safety, and efficacy of PL8177.

Palatin Technologies has commenced the recruitment of patients for a Phase II clinical trial of PL8177 to treat ulcerative colitis (UC).

Clinical trial sites that are taking part in the trial have been activated and the screening and recruitment of potential subjects is ongoing.

The double-blind, randomised, multi-centre, adaptive design, placebo-controlled, parallel group Phase II study has been designed to assess the tolerability, biomarkers, pharmacokinetics, safety, and efficacy of PL8177 in oral formulation in adult UC patients.

Up to 28 adult participants with active UC are planned to be enrolled from nearly 22 clinical trial locations.

In the study, all participants will be randomised and given either an oral dosing of PL8177 once a day or a placebo.

Palatin Technologies president and CEO Carl Spana said: “We are excited to advance oral PL8177, a potent, selective melanocortin-1 receptor agonist, into a Phase II clinical trial in patients with UC, an inflammatory bowel disease that affects an estimated one million people in the United States.

“The melanocortin system plays an important role in the resolution of inflammation. The oral formulation of PL8177 is targeting melanocortin-1 receptors on the luminal surface of colon epithelial cells.

“In a prior Phase I clinical study, the oral formulation successfully demonstrated sustained delivery of PL8177 to the lumen of the colon, with no systemic exposure.”

An oral potent human melanocortin receptor-1 (MC1r) agonist, PL8177 is a synthetic cyclic heptapeptide that has shown efficacy in several animal inflammatory bowel disease models.

It has been developed for resolving inflammation directly in the colon while avoiding broad immunosuppression, as well as adverse effects with selective compounds.

The oral formulation of PL8177 is designed to deliver the drug to the diseased bowel, increasing local treatment.

In the first quarter of next year, the interim assessment of PL8177-205 is expected to occur and final top line results are anticipated in the second quarter of the same year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena